[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spinal-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spinal-diseases":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,67],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100606149",false,"NCT07171801","Comparing 3D and 2D Views in Biportal Spine Surgery: A Pilot Simulation Study","3D vs. 2D Unilateral Biportal Endoscopic Spine Surgery: A Randomized Blinded Crossover Pilot Simulation Study","Inclusion Criteria:\n\n* Enrolled in the neurosurgical residency or fellowship program at the Department of Neurosurgery, Cantonal Hospital of St. Gallen, Switzerland\n* Completion of basic neurosurgical training modules, including introductory endoscopic handling\n* Age ≥ 18 years\n* Willingness and ability to provide informed consent\n\nExclusion Criteria:\n\n* Prior substantial experience with three-dimensional (3D) endoscopy (defined as \\> 5 independent procedures performed with 3D visualization systems)\n* Ocular or neurological conditions impairing stereopsis, fine motor control, or safe endoscope handling\n* Inability or unwillingness to complete the simulation protocol\n* Declined participation",true,"ALL","18 Years",{"count":19,"type":20},6,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to compare three-dimensional (3D) and two-dimensional (2D) visualization in biportal endoscopic spine surgery using a simulated environment. Surgeons will perform standardized tasks on a spine model while using either 3D or 2D endoscopic systems. The goal is to determine whether 3D technology can improve precision, efficiency, and movement control during surgery. The study uses a randomized, blinded, crossover design to ensure objective results and may help guide future training and technology use in spinal endoscopy.",[26,27,28,29,30,31],"Spinal Diseases","Endoscopy Simulation","Lumbar Vertebrae","Randomized Controlled Trial","Three-Dimensional","Simulation Training","NOT_YET_RECRUITING","2025-09-15",{"date":35,"type":36},"2025-09-16","ACTUAL",{"date":38,"type":20},"2025-10-01",{"date":40,"type":20},"2025-12-01",{"name":42,"class":43},"Felix Corr","OTHER",{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100606852","NCT07180940","Comparison of Perineural Dexamethasone Versus Dexmedetomidine as Adjuvants to Erector Spinae Plane Block in Lumbar Spine Surgery: A Randomized, Double-blind, Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 to N\u002FA (no limit)\n* Scheduled for elective lumbar spine surgery (e.g., decompression or fusion) via posterior approach\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Body weight ≥ 50 kg\n* Ability to provide written informed consent\n* Expected postoperative hospitalization of at least 48 hours\n\nExclusion Criteria:\n\n* Known allergy or contraindication to ropivacaine, dexamethasone, or dexmedetomidine\n* Infection at or near the site of block placement\n* Coagulation disorders or current use of anticoagulant therapy (not discontinued per guidelines)\n* Chronic opioid use or opioid dependence\n* Neurological or psychiatric disorders interfering with pain assessment\n* Diabetes mellitus with poorly controlled glycemia (e.g., HbA1c \\> 8%)\n* Severe hepatic or renal dysfunction\n* Body mass index (BMI) \\> 40 kg\u002Fm²\n* Pregnancy or breastfeeding\n* Refusal or inability to cooperate with the study protocol",{"count":50,"type":20},150,[52],"PHASE4","This clinical study aims to determine which of two medications-dexamethasone or dexmedetomidine-works better and is safer when used together with a local anesthetic (ropivacaine) in a type of nerve block called the erector spinae plane block (ESPB). This block helps reduce pain after lumbar spine surgery.",[55,26],"Spine Disease","RECRUITING","2025-09-12",{"date":59,"type":36},"2025-09-18",{"date":61,"type":36},"2025-09-01",{"date":63,"type":20},"2026-12-31",{"name":65,"class":43},"Poznan University of Medical Sciences",1,{"id":68,"slug":4,"hasResults":10,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":21,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":66},"100476486","NCT05484557","Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury","Inclusion Criteria:\n\n* spinal cord injury (traumatic of not traumatic), Hebrew speaker.\n\nExclusion Criteria:\n\n* contra-indication for anticoagulant treatment\n* concomitant treatment with any other anticoagulant\n* anticoagulant treatment needed for indications other than VTE prevention following spinal cord injury\n* active clinically significant bleeding\n* any lesion or condition considered a significant risk factor for major bleeding.\n* hepatic disease associated with coagulopathy and clinically relevant bleeding risk\n* pregnancy or breast-feeding\n* heart valve related issues\n* galactose intolerance\n* active cancer\n* patients who require thrombolysis or pulmonary embolectomy\n* patients with renal impairment\n* sensitivity to excipients of the medication\n* anti phospholipid syndrome\n* prosthetic heart valve\n* acute ischemic stroke",{"count":73,"type":20},60,[23],"Currently, Enoxaparin is the usual prophylactic anticoagulant treatment at the acute and sub-acute phases of spinal cord injury (SCI). Patients at the sub-acute phase of SCI (rehabilitation) will be given either Enoxaparin 40 mg\u002Fday (control) or Apixaban 2.5-5 mg twice a day. Apixaban dose will be determined by the treating physician. Treatment will be continued for either 6 or 12 weeks following injury (for AIS grades C-D and A-B respectively).\n\nEndpoints: Venous thromboembolism will be evaluated by D-Dimer test every 2 weeks and an ultrasound doppler at the beginning and the end of the treatment. Bleeding events will be recorded and hematocrit will be monitored every two weeks.",[77,26],"Spinal Cord Injuries","2025-05-06",{"date":80,"type":36},"2025-05-09",{"date":82,"type":36},"2023-09-06",{"date":84,"type":20},"2026-02",{"name":86,"class":43},"Loewenstein Hospital",""]